We demonstrate that XBP1 splicing is a valuable biomarker of NSCLC aggressiveness, and our results support a model in which IRE1 downstream signaling could act as a regulator of part of the EMT program. This evidence concerns the gene ERN1 and non-small cell lung carcinoma.